Mark Esq - Oncology Institute General Counsel
| TOI Stock | USD 0.17 0.02 13.33% |
Executive
Mark Esq is General Counsel of Oncology Institute
| Address | 18000 Studebaker Road, Cerritos, CA, United States, 90703 |
| Phone | 562 735 3226 |
| Web | https://theoncologyinstitute.com |
Oncology Institute Management Efficiency
The company has Return on Asset of (0.1942) % which means that on every $100 spent on assets, it lost $0.1942. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of (1.2559) %, meaning that it generated no profit with money invested by stockholders. Oncology Institute's management efficiency ratios could be used to measure how well Oncology Institute manages its routine affairs as well as how well it operates its assets and liabilities. The current Return On Tangible Assets is estimated to decrease to -0.47. The current Return On Capital Employed is estimated to decrease to -0.46. As of now, Oncology Institute's Asset Turnover is decreasing as compared to previous years.Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Edward Sim | Universal Health Services | 52 | |
| Brian Rusignuolo | Select Medical Holdings | 48 | |
| Gary Delanois | American Shared Hospital | 70 | |
| Tara Jones | Brookdale Senior Living | N/A | |
| Andrew Price | Encompass Health Corp | 57 | |
| Beth Gross | The Joint Corp | N/A | |
| Leland Thomas | agilon health | N/A | |
| Marissa Brittenham | Surgery Partners | 39 | |
| Brian Monahan | Addus HomeCare | N/A | |
| Thomas Day | Universal Health Services | N/A | |
| MS DO | Encompass Health Corp | 64 | |
| Geraldine Geckle | Universal Health Services | N/A | |
| Kirk Cheney | Pennant Group | N/A | |
| Danielle Burkhalter | Surgery Partners | 39 | |
| Elissa Charbonneau | Encompass Health Corp | 64 | |
| CPE MBA | Lifestance Health Group | 42 | |
| Cheryl VanPatten | Mednax Inc | N/A | |
| CPC MBA | Mednax Inc | N/A | |
| Jaclyn Pritchett | Brookdale Senior Living | 38 | |
| Varun Gadhok | Surgery Partners | N/A | |
| Nanette Sanders | Mednax Inc | N/A | |
Management Performance
| Return On Equity | -1.26 | ||||
| Return On Asset | -0.19 |
Oncology Institute Leadership Team
Elected by the shareholders, the Oncology Institute's board of directors comprises two types of representatives: Oncology Institute inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Oncology. The board's role is to monitor Oncology Institute's management team and ensure that shareholders' interests are well served. Oncology Institute's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Oncology Institute's outside directors are responsible for providing unbiased perspectives on the board's policies.
| FACHE MD, Chief Officer | ||
| Mark Esq, General Counsel | ||
| Rob Carter, Senior Finance | ||
| Bradford Hively, CEO Director | ||
| Rakesh MBA, Director Technology | ||
| Laura Szitar, Chief Officer | ||
| Richard Barasch, Executive Board | ||
| Jeremy MBA, Chief Officer | ||
| Diona CPA, Principal Officer | ||
| MBA JD, Senior Compliance | ||
| FACHE MBA, President | ||
| Philip Reger, Chief Officer | ||
| Julie Korinke, Director Communications | ||
| MD MBA, Chief Officer | ||
| Hilda MBA, Founder Officer | ||
| Mihir CPA, Chief Officer | ||
| Jordan McInerney, Chief Officer | ||
| Richy MD, Founder Officer | ||
| FACS MD, Chief Practice |
Oncology Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Oncology Institute a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -1.26 | ||||
| Return On Asset | -0.19 | ||||
| Profit Margin | (0.20) % | ||||
| Operating Margin | (0.17) % | ||||
| Current Valuation | 87 M | ||||
| Shares Outstanding | 75.56 M | ||||
| Shares Owned By Insiders | 19.55 % | ||||
| Shares Owned By Institutions | 47.59 % | ||||
| Number Of Shares Shorted | 247.97 K | ||||
| Price To Earning | 190.67 X |
Currently Active Assets on Macroaxis
When determining whether Oncology Institute offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Oncology Institute's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Oncology Institute Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Oncology Institute Stock:Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Oncology Institute. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in persons. For more detail on how to invest in Oncology Stock please use our How to Invest in Oncology Institute guide.You can also try the Stock Screener module to find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook..
Is Health Care Equipment & Supplies space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Oncology Institute. If investors know Oncology will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Oncology Institute listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.77) | Revenue Per Share 4.873 | Quarterly Revenue Growth 0.229 | Return On Assets (0.19) | Return On Equity (1.26) |
The market value of Oncology Institute is measured differently than its book value, which is the value of Oncology that is recorded on the company's balance sheet. Investors also form their own opinion of Oncology Institute's value that differs from its market value or its book value, called intrinsic value, which is Oncology Institute's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Oncology Institute's market value can be influenced by many factors that don't directly affect Oncology Institute's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Oncology Institute's value and its price as these two are different measures arrived at by different means. Investors typically determine if Oncology Institute is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Oncology Institute's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.